[go: up one dir, main page]

WO2006033995A3 - Thiazolidin-4-ones having anti-hepatitis b activity - Google Patents

Thiazolidin-4-ones having anti-hepatitis b activity Download PDF

Info

Publication number
WO2006033995A3
WO2006033995A3 PCT/US2005/033038 US2005033038W WO2006033995A3 WO 2006033995 A3 WO2006033995 A3 WO 2006033995A3 US 2005033038 W US2005033038 W US 2005033038W WO 2006033995 A3 WO2006033995 A3 WO 2006033995A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
thiazolidin
ones
activity
preventing
Prior art date
Application number
PCT/US2005/033038
Other languages
French (fr)
Other versions
WO2006033995A2 (en
Inventor
Robert K Hamatake
Huanming Chen
Anneke Raney
Matthew J Allan
Stanley Lang
Original Assignee
Valeant Res And Dev
Robert K Hamatake
Huanming Chen
Anneke Raney
Matthew J Allan
Stanley Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Res And Dev, Robert K Hamatake, Huanming Chen, Anneke Raney, Matthew J Allan, Stanley Lang filed Critical Valeant Res And Dev
Publication of WO2006033995A2 publication Critical patent/WO2006033995A2/en
Publication of WO2006033995A3 publication Critical patent/WO2006033995A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides compounds having the following general structure (I): wherein X is S, O, or N and X’ is N or C. The compounds are useful for preventing and treating hepatitis B virus (HBV) infections in mammals, and for preventing and treating diseases associated with HBV infection.
PCT/US2005/033038 2004-09-16 2005-09-16 Thiazolidin-4-ones having anti-hepatitis b activity WO2006033995A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61049404P 2004-09-16 2004-09-16
US60/610,494 2004-09-16

Publications (2)

Publication Number Publication Date
WO2006033995A2 WO2006033995A2 (en) 2006-03-30
WO2006033995A3 true WO2006033995A3 (en) 2006-06-01

Family

ID=36090506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033038 WO2006033995A2 (en) 2004-09-16 2005-09-16 Thiazolidin-4-ones having anti-hepatitis b activity

Country Status (1)

Country Link
WO (1) WO2006033995A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233978B2 (en) 2014-03-07 2016-01-12 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US9266904B2 (en) 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US9856247B2 (en) 2012-03-31 2018-01-02 Hoffmann-La Roche Inc. 4-methyl-dihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
US11337982B2 (en) 2016-09-13 2022-05-24 Hoffmann-La Roche, Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11771699B2 (en) 2015-03-16 2023-10-03 Hoffmann-La Roche Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11873302B2 (en) 2019-03-25 2024-01-16 Hoffmann-La Roche Inc. Solid forms of a compound of HBV core protein allosteric modifier

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130793B (en) * 2011-11-30 2016-09-21 中国人民解放军军事医学科学院毒物药物研究所 3-(1-Arylpiperidine-4-base)-2-aryl thiazole quinoline-4-ketone compounds, Preparation Method And The Use
CA2865259A1 (en) 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR20150054795A (en) 2012-09-10 2015-05-20 에프. 호프만-라 로슈 아게 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN103664916B (en) * 2012-09-12 2016-08-24 中国科学院化学研究所 Conjugation small molecule material based on sub-two pyrroles of bithiophene and derivant thereof and preparation method and application
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153100A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
WO2014153090A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives asprmt1 inhibitors and uses thereof
KR102028793B1 (en) 2013-03-14 2019-10-07 에피자임, 인코포레이티드 Arginine methyl transferase inhibitors and uses thereof
JP2016514164A (en) 2013-03-14 2016-05-19 エピザイム，インコーポレイティド Pyrazole derivatives and their use as arginine methyltransferase inhibitors
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2017064156A1 (en) 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
MX384836B (en) 2016-03-07 2025-03-14 Enanta Pharm Inc ANTIVIRAL AGENTS AGAINST HEPATITIS B
KR102083818B1 (en) 2016-04-06 2020-03-03 상하이 지멍 바이오파마 컴퍼니 리미티드 Anti-Hepatitis B Virus Pyrazole-Oxazolidinone Compound
WO2017214395A1 (en) 2016-06-10 2017-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN111263586B (en) 2017-08-28 2021-12-03 英安塔制药有限公司 Hepatitis B antiviral agent
AR115131A1 (en) 2017-11-02 2020-12-02 Aicuris Gmbh & Co Kg HIGHLY ACTIVE INDOLO-2-CARBOXAMIDES REPLACED WITH PYRAZOLO-PYRIMIDINE ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
SG11202003700TA (en) 2017-11-02 2020-05-28 Aicuris Gmbh & Co Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
TW201936192A (en) 2017-12-06 2019-09-16 美商因那塔製藥公司 Hepatitis B antiviral agents
TW201927789A (en) 2017-12-06 2019-07-16 美商因那塔製藥公司 Hepatitis B antiviral agents
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
AU2019342750A1 (en) 2018-09-21 2021-04-08 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
UY38436A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
AR117188A1 (en) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
UY38434A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
AR116948A1 (en) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AR116946A1 (en) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [4,3-C] PYRIDINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
US20220009945A1 (en) 2018-11-02 2022-01-13 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv)
CN113271946A (en) 2018-11-21 2021-08-17 英安塔制药有限公司 Functionalized heterocyclic compounds as antiviral agents
JP2022533007A (en) 2019-04-30 2022-07-21 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト A novel indolizine-2-carboxamide that is active against hepatitis B virus (HBV)
CU20210088A7 (en) 2019-04-30 2022-06-06 Aicuris Gmbh & Co Kg COMPOUNDS SUBSTITUTED DERIVATIVES OF INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
KR20220003023A (en) 2019-04-30 2022-01-07 아이쿠리스 게엠베하 운트 코. 카게 Novel oxalyl piperazine active against hepatitis B virus (HBV)
US20220227785A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN112574188B (en) * 2019-09-29 2022-05-06 苏州爱科百发生物医药技术有限公司 A kind of pyrazole compound and its application
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN114685473B (en) * 2020-12-25 2024-10-29 杭州百新生物医药科技有限公司 5-Alkyl-2-pyrazole-oxazolidine-4-ketone derivative and application thereof
CN115677680A (en) * 2021-07-23 2023-02-03 上海挚盟医药科技有限公司 Crystal forms of compound of formula I, preparation and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAS [online] CHARY ET AL, accession no. STN Database accession no. 1992:612383 *
INDIAN JOURNAL OF CHEMISTRY, SECTION B; ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 31B, no. 8, 1992 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856247B2 (en) 2012-03-31 2018-01-02 Hoffmann-La Roche Inc. 4-methyl-dihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
US9266904B2 (en) 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US9758530B2 (en) 2013-05-17 2017-09-12 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US9233978B2 (en) 2014-03-07 2016-01-12 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US10081627B2 (en) 2014-03-07 2018-09-25 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US10428069B2 (en) 2014-03-07 2019-10-01 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US11771699B2 (en) 2015-03-16 2023-10-03 Hoffmann-La Roche Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11337982B2 (en) 2016-09-13 2022-05-24 Hoffmann-La Roche, Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11873302B2 (en) 2019-03-25 2024-01-16 Hoffmann-La Roche Inc. Solid forms of a compound of HBV core protein allosteric modifier

Also Published As

Publication number Publication date
WO2006033995A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2003093290A8 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2004028481A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2007084413A3 (en) Methods for treating hepatitis c
BRPI0415883A (en) nucleoside compounds and compositions for the treatment of viral infections
CA2413163A1 (en) 3'-prodrugs of 2'-deoxy-.beta.-l-nucleosides
WO2006130627A3 (en) Methods for treating hepatitis c
EA200700243A1 (en) METHODS OF TREATMENT OF HEPATITIS C
EP2361913A8 (en) Anti-infective agents
AU2003249977A1 (en) Imidazole compounds for the treatment of hepatitis c virus infections
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
ATE490778T1 (en) USE OF ÄD-MEALAÜ3-ÄETVALÜ4-CICLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION
WO2006075993A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
WO2007084435A8 (en) Methods for treating hepatitis c
WO2001045712A8 (en) Combinations of medicaments for treating viral diseases
WO2007002639A3 (en) Non-nucleoside anti-hepacivirus agents and uses thereof
EP1256348A4 (en) REMEDIES AGAINST HEPATITIS C
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
WO2008100547A3 (en) Compositions comprising lamiridosin, iridoids or derivatives thereof for treatment of hepatitis c or hepatitis b
WO2004078127A3 (en) Continuous delivery methods for treating hepatitis virus infection
EP1765330A4 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase